Miami Breast Cancer Conference

Hurvitz Discusses Anthracycline Versus Non-Anthracycline Regimens

March 13, 2017

Sara A. Hurvitz, MD, discusses the pros and cons of anthracycline treatment.

Current Therapies in Early-Stage HER2+ Breast Cancer

March 13, 2017

Mohammad Jahanzeb, MD, discusses the designs of landmark trials in early HER2-positive targeted therapy and the adverse events associated with those treatments.

Options in Overcoming Resistance to HER2-Targeted Therapy

March 13, 2017

Mark D. Pegram, MD, discusses proposed mechanisms of resistance to HER2-targeted therapies.

An Overview of the MONARCH and NeoMONARCH Trials in Breast Cancer

March 12, 2017

Joyce A. O’Shaughnessy, MD, chair of Breast Cancer Research and the Celebrating Women Chair in Breast Cancer at Baylor-Sammons Cancer Center, discusses the ongoing MONARCH and neoMONARCH studies in breast cancer.

Healthcare Utilization and Costs Remain High for TNBC, Study Shows

March 12, 2017

According to a retrospective 4.5-year study of patients who had commercial and Medicare supplemental coverage, healthcare resource use and costs remain high among patients with metastatic triple-negative breast cancer.

Immunotherapy Combos Represent the Future of Breast Cancer Treatment

March 12, 2017

Elizabeth A. Mittendorf, MD, PhD, discusses the immunotherapy combinations currently being investigated in the treatment of breast cancer.

PARP Inhibitors Likely This Year's Breakthrough In Breast Cancer Management

March 12, 2017

Kimberly Blackwell, MD, discusses the results of the recent phase III OLYMPIAD trial, which showed olaparib (Lynparza) improved progression-free survival (PFS) versus standard chemotherapy in patients with BRCA-positive breast cancer.

Incorporating Biologic Factors Into Breast Cancer Staging

March 12, 2017

Kelly K. Hunt, MD, professor of Surgery, and chair, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses incorporating biologic factors into breast cancer staging.

Targeting the Androgen Receptor in Breast Cancer

March 11, 2017

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses targeting the androgen receptor in breast cancer.

Improved Outcomes Seen With Novel Agents in HR+ Breast Cancer

March 11, 2017

The addition of CDK4/6 and mTOR inhibitors to standard endocrine therapy has significantly improved outcomes in patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer.